OHSU researchers identify new tools for early cancer detection, treatment
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-Nov-2025 19:11 ET (6-Nov-2025 00:11 GMT/UTC)
Targeting a specialized group of histones is safe and opens new therapeutic opportunities for treating blood cancers. This is the main finding of the latest research by Dr Marcus Buschbeck and Dr René Winkler, researchers at the Josep Carreras Leukaemia Research Institute. Experimental results confirm that the removal of any of the three proteins of the macroH2A family of histones, linked to Acute Myeloid Leukaemia, is well tolerated in mice and has no major effect on their health.
- Science learns from nature's methods
- Potential benefits for future therapies against cancer and Alzheimer's disease
- Joint research by TUM and Helmholtz Munich
In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes. However, cancer cells often manage to override this mechanism. A research team at the Technical University of Munich (TUM) has now succeeded in identifying a new molecular switch in this process and elucidating how it works.
Solid tumours, which account for around 90 per cent of all adult cancers, remain a major challenge for CAR T cells to infiltrate.Researchers in Australia have used CRISPR-based gene editing or a PTPN2 inhibitor to enhance the function of human CAR T cells engineered to recognize an antigen expressed on many solid tumours.